NEW YORK (GenomeWeb News) — CollabRx and CellNetix Pathology & Laboratories have signed a multi-year agreement that lets CellNetix make use of CollabRx's technology and content resources in providing sequencing-based testing for oncology.
Under the terms of the agreement announced today, Seattle-based CellNetix will include medical and scientific information from CollabRx's knowledgebase into its test results. The knowledgebase contains data on the clinical impact of specific genetic profiles and it is supported by CollabRx's network of more than 75 clinical practitioners. Having access to this information will ensure that physicians ordering tests from CellNetix use current data to interpret results and make treatment decisions, the partners said.
"CollabRx has developed a highly scalable technology platform and process to provide a key part of the diagnostic test report for clinical genetic sequencing in cancer," according to Pat Cooke, CellNetix CIO & executive director of business operations at CellNetix. "These IT tools and services are essential to dynamically associate the latest medical and
scientific knowledge with the results of tumor mutation profiling conducted by CellNetix."
The CellNetix partnership is CollabRx's first relationship with a large, private pathology company, it said. The financial details of the arrangement were not disclosed.